316 related articles for article (PubMed ID: 21459936)
21. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
[TBL] [Abstract][Full Text] [Related]
22. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW
Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
[TBL] [Abstract][Full Text] [Related]
23. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
24. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.
Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Chon Y; Zhang N; Baumgartner SW
Arthritis Rheum; 2010 Nov; 62(11):3259-64. PubMed ID: 20669280
[TBL] [Abstract][Full Text] [Related]
25. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
Borte S; Liebert UG; Borte M; Sack U
Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
[TBL] [Abstract][Full Text] [Related]
27. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
Schmeling H; Horneff G
Rheumatology (Oxford); 2005 Aug; 44(8):1008-11. PubMed ID: 15855187
[TBL] [Abstract][Full Text] [Related]
28. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.
Nordal E; Zak M; Aalto K; Berntson L; Fasth A; Herlin T; Lahdenne P; Nielsen S; Straume B; Rygg M;
Arthritis Rheum; 2011 Sep; 63(9):2809-18. PubMed ID: 21560116
[TBL] [Abstract][Full Text] [Related]
29. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
Smith JA; Thompson DJ; Whitcup SM; Suhler E; Clarke G; Smith S; Robinson M; Kim J; Barron KS
Arthritis Rheum; 2005 Feb; 53(1):18-23. PubMed ID: 15696578
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
31. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
Lovell DJ; Giannini EH; Reiff A; Cawkwell GD; Silverman ED; Nocton JJ; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore J; Finck BK
N Engl J Med; 2000 Mar; 342(11):763-9. PubMed ID: 10717011
[TBL] [Abstract][Full Text] [Related]
32. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
[TBL] [Abstract][Full Text] [Related]
34. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
Vojvodich PF; Hansen JB; Andersson U; Sävendahl L; Hagelberg S
J Rheumatol; 2007 Dec; 34(12):2481-5. PubMed ID: 18050366
[TBL] [Abstract][Full Text] [Related]
35. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
[TBL] [Abstract][Full Text] [Related]
36. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
Papsdorf V; Horneff G
Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Ilowite NT; Wallace CA; Chon Y; Lin SL; Baumgartner SW; Giannini EH;
Arthritis Rheum; 2008 May; 58(5):1496-504. PubMed ID: 18438876
[TBL] [Abstract][Full Text] [Related]
38. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
[TBL] [Abstract][Full Text] [Related]
39. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
40. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
